A retrospective observational study to assess prescribing practices of concomitant Direct oral anticoagulants (DOACs) and antiplatelet use in critically ill patients
Latest Information Update: 24 Dec 2021
Price :
$35 *
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary) ; Antiplatelets
- Indications Deep vein thrombosis; Pulmonary embolism
- Focus Adverse reactions
- 24 Dec 2021 New trial record